Latest news with #Femtech
Yahoo
13-05-2025
- Business
- Yahoo
U.S. Patent and Trademark Office Granted Femto Technologies Inc. A Notice of Allowance for Use of Its Sensera Design
LOS ANGELES, CA - May 13, 2025 (NEWMEDIAWIRE) - Femto Technologies Inc. (Nasdaq: FMTO), a pioneering Femtech company formerly known as BYND Cannasoft Enterprises Inc., announced today that the U.S. Patent and Trademark Office (USPTO) has granted it a Notice of Allowance for its female treatment device - Sensera design. This milestone reinforces Femto's commitment to redefining wellness solutions through AI-driven advancements. The unique design of the Sensera device is a fundamental component of Femto's innovative Femtech products, which was recently recognized as a CES Innovation Awards(R) 2025 honoree in the AI category. This prestigious accolade underscores Femto's leadership in cutting-edge technology tailored to enhance wellness for all. "Receiving the Notice of Allowance from the U.S. Patent and Trademark Office marks another significant milestone for Femto Technologies. Our proprietary Smart Release System technology along with the cutting-edge design is at the forefront of innovation, driving transformative advancements in Femtech. This recognition reinforces our commitment to pioneering AI-driven wellness solutions that enhance lives globally," Yftah Ben Yaackov, CEO, Femto Technologies Inc. Femto's R&D initiatives and product development are heavily driven by its SRS technology with applications spanning a variety of Femtech solutions. The company remains committed to rigorous testing, research, and regulatory compliance to ensure the efficacy and safety of its products. About Femto Technologies Inc. Femto Technologies Inc. (Nasdaq: FMTO) is a cutting-edge Femtech company spearheading transformative advancements in wellness technology. With a strong emphasis on AI-driven solutions, Femto is dedicated to innovating products that enhance well-being through intelligent technology integration. ABOUT SENSERA Sensera is a feminine wellness device on a mission to bridge the gap between feminine pleasure and wellness, providing a holistic self-care experience that adapts to a woman's changing needs. Sensera utilizes Femto's proprietary Smart Release System (SRS) technology, including machine learning and AI, to enhance feminine wellness. Sensera is a CES Innovation Awards(R) 2025 Honorary in the AI category. For more information on Sensera, please visit and follow us on Instagram, Facebook, and YouTube. MEDIA CONTACTFor product demonstration and mediaSamantha BreenOpportunity PR (for Sensera)samantha@ 949.290.2834 COMPANY CONTACTGabi KabazoChief Financial OfficerTel: (604) 833-6820email: ir@ press release includes certain statements that may be deemed "forward-looking statements" within the meaning of Section 27A of the U.S. Securities Act of 1933, as amended, and Section 21E of the U.S. Securities Exchange Act of 1934, as amended and under Canadian securities laws. When used in this press release, the words "may", "would", "could", "will", "intend", "plan", "anticipate", "believe", "estimate", "expect" and similar expressions are intended to identify forwardlooking statements. Such statements are subject to certain risks and uncertainties, and actual circumstances, events or results may differ materially from those projected in such forward-looking statements. Although the Company believes the expectations expressed in such forward-looking statements are based on reasonable assumptions, such statements are not guarantees of future performance, and actual events or developments may differ materially from those in forward-looking statements. Such forward-looking statements necessarily involve known and unknown risks and uncertainties, which may cause the Company's actual performance and financial results in future periods to differ materially from any projections of future performance or results expressed or implied by such forward-looking statements. Such statements reflect the Company's current views with respect to future events and are subject to such risks and uncertainties. Many factors could cause actual results to differ materially from the statements made, including future financial performance, unanticipated regulatory requests and delays, final patents approval, and those factors discussed in filings made by the company with the Canadian securities regulatory authorities, including (without limitation) in the company's management's discussion and analysis for the year ended December 31, 2024 and annual information form dated March 31, 2025, which are available under the company's profile at and in the Company's Annual Report on Form 20-F for the year then ended that was filed with the U.S. Securities and Exchange Commission on March 31, 2025. Should one or more of these factors occur, or should assumptions underlying the forward-looking statements prove incorrect, actual results may vary materially from those described herein as intended, planned, anticipated, or expected. We do not intend and do not assume any obligation to update these forwardlooking statements, except as required by law. Any such forward-looking statements represent management's estimates as of the date of this press release. While we may elect to update such forward-looking statements at some point in the future, we disclaim any obligation to do so, even if subsequent events cause our views to change. Shareholders are cautioned not to put undue reliance on such forwardlooking statements. View the original release on Error in retrieving data Sign in to access your portfolio Error in retrieving data Error in retrieving data Error in retrieving data Error in retrieving data
Yahoo
04-04-2025
- Business
- Yahoo
Can Hailey Bieber Break Beauty's M&A Slowdown?
Can Hailey Bieber break the beauty M&A curse? Sources have confirmed to WWD that her beauty brand Rhode has hired J.P. Morgan and Moelis to jointly explore deal options at a valuation of $1 billion, after a bevy of brands entered the market in the last year that never culminated in deals. Rhode's sales are understood to be around $200 million. More from WWD Unilever Snaps Up British Sustainable Deodorant Brand Wild Inside Sephoria's Italian Debut EXCLUSIVE: Wearable Breast Pump Company Willow Acquires Like-minded Femtech Company Elvie Neither Rhode, J.P. Morgan nor Moelis could be reached for comment by press time. News of the deal raised eyebrows among industry sources with knowledge of the brand's financials. One industry source said that while the target would be a strategic buyer, that could be difficult given that the business is currently all online, despite speculation that it is gearing up to go with a retailer. 'They're too risk-averse, particularly in this environment,' another source said of potential strategic buyers. 'The market is just too uncertain to write that big of a check.' Even if Rhode does soon reveal an exclusive partnership with a major retailer, investors are jittery about acquiring brands tied to one celebrity and one retailer, as it is often believed to be a risky strategy, multiple sources said. The news comes at a time when significant transactions have been few and far between. Among the brands that reportedly came to market in the last 12 months but are yet to score a deal are Rare Beauty, Makeup by Mario, Merit, Kosas, Byoma and Jane Iredale, among others. 'Nobody paid $1 billion for Rare Beauty, nobody paid $1 billion for Makeup by Mario,' said one source, citing the lagging M&A market and broader economic pressures. 'Why would they pay that for Rhode? It doesn't even have distribution.' While one source posited that it would make sense for acquirers to snap up the brand before it enters retail — and then reap the rewards as owners — broader market trends point away from that scenario. 'The brand has approached the scale where the universe of potential buyers is getting smaller and smaller,' said the source. 'And [Makeup by Mario, Rare Beauty and Rhode] are too young, too big, too dependent on their founders — there's too much risk. The buyers that are relevant are exactly the buyers that wouldn't touch this.' Skin care, which Rhode launched with before expanding into color cosmetics and accessories, is also seeing a slowdown in the U.S., though Rhode falls in the 'masstige' price range that is still growing, as reported. And though Rhode is understood to be lining up specialty retail partnerships in key markets globally (speculation has swirled for months about an impending deal with Sephora in North America), the logistics alone could hamper brand leadership. 'It's not just shipping products to Sephora or flying Hailey around. People think getting into Sephora is a big win, but can they support that?' one source said. Despite the marketing prowess of Rhode's founder, both potential buyers and retail partners are beginning to see social media savvy as a con, not a pro. 'Brands are being told to dial that back,' said a source. 'Don't get hooked on virality, because you can't anniversary those sales numbers. That's not viewed favorably. It drives traffic, sure, but you don't want massive spikes.' Rhode also pumps money into marketing beyond the fame of Bieber, tapping talent for campaigns ranging from Claudia Schiffer and Paloma Elsesser to Matilda Djerf. Despite that, the business is assumed to be profitable, with one source estimating the cost of goods at around 15 percent and referencing the brand's ownership of its own margins, since it sells directly. 'That would give Hailey about $170 million to spend on marketing, people and logistics,' the source hypothesized. 'It's a lot of dollars to play with. My guess is she's profitable and, by the way, if she's not, then they're definitely not getting this deal done.' On the bright side, the market has begun to thaw for smaller deals. Skims, Kim Kardashian's shapewear and apparel company, has acquired Skkn by Kim from Kim Kardashian and Coty Inc. Coty acquired 20 percent of KKW Beauty for $200 million in 2021. Now that stake will belong to Skims, while Kardashian's 80 percent holding will also be transferred to Skims. Unilever also acquired British sustainable deodorant brand Wild. While it did not reveal the price paid, it has been reported that it sold for 230 million pounds. Best of WWD How Grooming Is Introducing Men to Self-care and Redefining Masculinity Clean Beauty Brand Ignae Makes Big U.S. Push With a New Look War Paint for Men Opens First Store in London's Carnaby Street
Yahoo
20-02-2025
- Health
- Yahoo
Fertility and period tracker-use rises since Dobbs decision, in Ohio and elsewhere
(Photo illustration by) Researchers with the Ohio State University were part of a study that's found an increase in the use of fertility and period trackers despite public concerns about information privacy and reproductive rights regulations. The study, released in the journal Contraception this month, used survey samples of people who used technology known as 'Femtech,' or apps and technology 'aimed at improving women's health' with features like fertility tracking and period calendars. 'While there are still uncertainties about privacy policies related to period tracking, the findings may have a broader implication: the need for users to consider whether they can trust technology to accurately predict or prevent pregnancy,' said Emily Neiman, clinical instructor of practice in the OSU College of Nursing, and lead author of the study. Researchers used data from the Survey of Women, conducted by NORC at the University of Chicago (formerly the National Opinion Research Center). For nearly a decade, the survey has been conducted to track reproductive health access, contraceptive use and abortion prevalence for women ages 18 to 44 in nine states: Ohio, Alabama, Arizona, Delaware, Iowa, Maryland, New Jersey, South Carolina and Wisconsin, according to NORC. 'The Survey of Women questionnaire has evolved to capture how the COVID-19 pandemic and the U.S. Supreme Court ruling in Dobbs v. Jackson Women's Health Organization have impacted reproductive health care access, delivery and reproductive health outcomes,' the research center stated on its web page. The Dobbs decision was the ruling from the U.S. Supreme Court in 2022 that overturned the 1973 Roe v. Wade ruling, which legalized abortion nationwide. Survey data gets disseminated to 'evaluation teams' at Ohio State, the Guttmacher Institute, East Tennessee State, and the University of Maryland. The most recent Ohio State study using information from the survey used Ohio, Arizona, Iowa, New Jersey, and Wisconsin data to compare the use of period or fertility-tracking technology and the reasons for use before and after the Dobbs ruling in June 2022. Neiman said the study began after public fears arose that personal data from period and fertility trackers could be 'used against them.' Those fears led to calls in Ohio and elsewhere for users to delete the apps and their information from them. 'It doesn't seem like people heeded the advice to stop using fertility trackers, and there could be a number of reasons for that,' Neiman said. 'Potentially, more people are using tracking to recognize a pregnancy as early as possible so they have the most options or so they can seek prenatal care early, but there may be fewer people planning pregnancy now that there are these restrictions around abortion.' In Ohio, abortion is legal up to fetal viability as a result of a state constitutional amendment passed by voters in 2023 protecting reproductive rights, including abortion. SUBSCRIBE: GET THE MORNING HEADLINES DELIVERED TO YOUR INBOX Researchers found that frequency of use for the technology 'increased overall and in all states but Wisconsin, where the prevalence was unchanged.' The study found that 37.4% of women in the five states used the technologies before the Dobbs decision, and 45.2% used it after. In Ohio, the study showed 34.2% of survey participants used apps before Dobbs, and that number rose to 44% after the decision. According to a Kaiser Family Foundation national survey, since 2019 almost one-third of people who are able to get pregnant used an internet or smartphone-based technology to keep track of menstrual cycles or fertility. But the details of what is tracked vary from app to app, and whether or not it's a paid service or a free one, researchers at Ohio State found. That includes the accuracy of the information, according to the study. 'While users may benefit from these technologies, their use may cause harm if user-entered data or predictions are incorrect,' the study stated. 'Additionally, sharing personal health details with period- or fertility-tracking technologies may carry risk, including the potential for privacy violations and data-sharing or selling.' The study noted that not only did the Dobbs decision occur during the time period being researched, but 'a large rise in the adoption of mobile health technologies due to the COVID-19 pandemic and the resulting decreased access to in-person care and increased access to and reliance on telemedicine' also may have contributed to the significant rise in period and fertility-tracking use. With the growth in popularity of these apps, Neiman said users should work to 'understand potential limitations of app fertility predictions' and for physicians to 'broach the subject of Femtech use in conversations with patients.' 'As providers and public health professionals, we could be doing a better job of educating around the reliability of the information they're getting from these technologies to help people who are trying to prevent unwanted pregnancies,' Neiman said. SUPPORT: YOU MAKE OUR WORK POSSIBLE
